Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Completes Enrollment of PV-10® Study for Treatment of Symptomatic Neuroendocrine Tumors Metastatic to the Liver Refractory to Somatostatin Analogs and Peptide Receptor Radionuclide Therapy

Company plans to seek end-of-phase meeting with Australia’s Therapeutic Goods Administration in Q1 2021 KNOXVILLE, TN, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today...
August 27, 2019 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

PV-10-based Cancer Combination Therapy Clinical Trial Design Wins Australasian Gastro-Intestinal Trials Group’s New Concepts Award

Two-stage, 34-patient, Phase 2 study combines PV-10 and Keytruda® (pembrolizumab) for treatment of metastatic neuroendocrine tumorsCombination powered for 19% ORR vs 3.7% ORR for Keytruda...